Terminal · Institutions

Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.

GREAT POINT PARTNERS LLC 13F Holdings -- Portfolio & Top Positions (2026-06-30)

GREAT POINT PARTNERS LLC (CIK 1281446) reported $529.1M across 37 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: ABVX ($80.5M, 15.22%), VOR ($31.3M, 5.91%), IBRX ($26.3M, 4.97%), VERA ($25.8M, 4.87%), ZURA ($24.9M, 4.70%). Source: SEC Form 13F.

RankTickerCompanyValue% PortfolioSharesAction
1ABVXABIVAX SA$80.5M15.22%604,314New
2VORVOR BIOPHARMA INC$31.3M5.91%1.7MTrimmed
3IBRXIMMUNITYBIO INC$26.3M4.97%3.0MHold
4VERAVERA THERAPEUTICS INC$25.8M4.87%600,836Added
5ZURAZURA BIO LTD$24.9M4.70%4.2MHold
6ALMSALUMIS INC$24.1M4.55%856,061Hold
7SLGLSOL-GEL TECHNOLOGIES LTD$20.3M3.84%274,363Hold
8RAREULTRAGENYX PHARMACEUTICAL IN$20.0M3.79%600,000New
9ANNXANNEXON INC$20.0M3.78%3.5MAdded
10DFTXDEFINIUM THERAPEUTICS INC$20.0M3.78%425,000New
11ORKAORUKA THERAPEUTICS INC$17.4M3.30%183,330Hold
12MLTXMOONLAKE IMMUNOTHERAPEUTICS$16.7M3.15%855,813Added
13SGMTSAGIMET BIOSCIENCES INC$15.7M2.97%2.0MNew
14CTNMCONTINEUM THERAPEUTICS INC$15.1M2.85%921,481Added
15IMMXIMMIX BIOPHARMA INC$13.2M2.49%1.3MAdded
16CLYMCLIMB BIO INC$13.0M2.46%1.0MTrimmed
17AMLXAMYLYX PHARMACEUTICALS INC$12.6M2.38%700,000Trimmed
18NKTRNEKTAR THERAPEUTICS$12.2M2.31%175,000Trimmed
19NGNENEUROGENE INC$11.1M2.09%352,180Trimmed
20LBRXLB PHARMACEUTICALS INC$10.3M1.95%317,221Added
21IRDOPUS GENETICS INC$8.1M1.53%2.0MAdded
22EPRXEUPRAXIA PHARMACEUTICALS INC$7.9M1.50%1.2MHold
23DRUGBRIGHT MINDS BIOSCIENCES INC$7.7M1.45%109,603Trimmed
24IFRXINFLARX NV$6.8M1.29%3.0MNew
25RLMDRELMADA THERAPEUTICS INC$5.8M1.10%842,106Hold

Source: SEC Form 13F filings · as of 2026-06-30